US20180155341A1 - Antibacterial Compounds - Google Patents

Antibacterial Compounds Download PDF

Info

Publication number
US20180155341A1
US20180155341A1 US15/736,524 US201615736524A US2018155341A1 US 20180155341 A1 US20180155341 A1 US 20180155341A1 US 201615736524 A US201615736524 A US 201615736524A US 2018155341 A1 US2018155341 A1 US 2018155341A1
Authority
US
United States
Prior art keywords
optionally substituted
alkyl
ring
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/736,524
Other languages
English (en)
Inventor
Jérôme Émile Georges Guillemont
Magali Madeleine Simone Motte
Pierre Jean-Marie Bernard Rabiosson
Abdellah Tahri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Janssen Cilag SAS
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56289523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20180155341(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Publication of US20180155341A1 publication Critical patent/US20180155341A1/en
Assigned to JANSSEN-CILAG reassignment JANSSEN-CILAG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GUILLEMONT, Jérôme Émile Georges, MOTTE, MAGALI MADELEINE SIMONE
Assigned to JANSSEN PHARMACEUTICA NV reassignment JANSSEN PHARMACEUTICA NV ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RABOISSON, PIERRE JEAN-MARIE BERNARD, TAHRI, ABDELLAH
Assigned to JANSSEN SCIENCES IRELAND UC reassignment JANSSEN SCIENCES IRELAND UC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JANSSEN-CILAG
Assigned to JANSSEN SCIENCES IRELAND UC reassignment JANSSEN SCIENCES IRELAND UC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JANSSEN PHARMACEUTICA NV
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to novel compounds.
  • the invention also relates to such compounds for use as a pharmaceutical and further for the use in the treatment of bacterial diseases, including diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis .
  • Such compounds may work by interfering with ATP synthase in M. tuberculosis , with the inhibition of cytochrome bc 1 activity as the primary mode of action.
  • cytochrome bc 1 activity as the primary mode of action.
  • such compounds are antitubercular agents.
  • Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), a serious and potentially fatal infection with a world-wide distribution.
  • TB tuberculosis
  • Estimates from the World Health Organization indicate that more than 8 million people contract TB each year, and 2 million people die from tuberculosis yearly. In the last decade, TB cases have grown 20% worldwide with the highest burden in the most impoverished communities. If these trends continue, TB incidence will increase by 41% in the next twenty years. Fifty years since the introduction of an effective chemotherapy, TB remains after AIDS, the leading infectious cause of adult mortality in the world. Complicating the TB epidemic is the rising tide of multi-drug-resistant strains, and the deadly symbiosis with HIV. People who are HIV-positive and infected with TB are 30 times more likely to develop active TB than people who are HIV-negative and TB is responsible for the death of one out of every three people with HIV/AIDS worldwide
  • MDR-TB multi-drug-resistant strains
  • MDR-TB multi-drug-resistant strains
  • drug resistant as used hereinbefore or hereinafter is a term well understood by the person skilled in microbiology.
  • a drug resistant Mycobacterium is a Mycobacterium which is no longer susceptible to at least one previously effective drug; which has developed the ability to withstand antibiotic attack by at least one previously effective drug.
  • a drug resistant strain may relay that ability to withstand to its progeny. Said resistance may be due to random genetic mutations in the bacterial cell that alters its sensitivity to a single drug or to different drugs.
  • MDR tuberculosis is a specific form of drug resistant tuberculosis due to a bacterium resistant to at least isoniazid and rifampicin (with or without resistance to other drugs), which are at present the two most powerful anti-TB drugs.
  • drug resistant includes multi drug resistant.
  • the dormant TB can get reactivated to cause disease by several factors like suppression of host immunity by use of immunosuppressive agents like antibodies against tumor necrosis factor ⁇ or interferon- ⁇ .
  • immunosuppressive agents like antibodies against tumor necrosis factor ⁇ or interferon- ⁇ .
  • the only prophylactic treatment available for latent TB is two-three months regimens of rifampicin, pyrazinamide.
  • the efficacy of the treatment regime is still not clear and furthermore the length of the treatments is an important constrain in resource-limited environments. Hence there is a drastic need to identify new drugs, which can act as chemoprophylatic agents for individuals harboring latent TB bacilli.
  • the tubercle bacilli enter healthy individuals by inhalation; they are phagocytosed by the alveolar macrophages of the lungs. This leads to potent immune response and formation of granulomas, which consist of macrophages infected with M. tuberculosis surrounded by T cells. After a period of 6-8 weeks the host immune response cause death of infected cells by necrosis and accumulation of caseous material with certain extracellular bacilli, surrounded by macrophages, epitheloid cells and layers of lymphoid tissue at the periphery.
  • Self-medication with antimicrobials is another major factor contributing to resistance.
  • Self-medicated antimicrobials may be unnecessary, are often inadequately dosed, or may not contain adequate amounts of active drug.
  • Patient compliance with recommended treatment is another major problem. Patients forget to take medication, interrupt their treatment when they begin to feel better, or may be unable to afford a full course, thereby creating an ideal environment for microbes to adapt rather than be killed.
  • Anti-infective compounds for treating tuberculosis have been disclosed in e.g. international patent application WO 2011/113606. Such a document is concerned with compounds that would prevent M. tuberculosis multiplication inside the host macrophage and relates to compounds with a bicyclic core, imidazopyridines, which are linked (e.g. via an amido moiety) to e.g. an optionally substituted benzyl group.
  • the purpose of the present invention is to provide compounds for use in the treatment of bacterial diseases, particularly those diseases caused by pathogenic bacteria such as Mycobacterium tuberculosis (including the latent disease and including drug resistant M. tuberculosis strains).
  • Such compounds may also be novel and may act by interfering with ATP synthase in M. tuberculosis , with the inhibition of cytochrome bc 1 activity being considered the primary mode of action.
  • R 1 represents C 1-6 alkyl or hydrogen
  • L 1 represents a linker group —C(R a )(R b )— (or is not present);
  • Het represents a heteroaromatic linker group (which linker group may itself be optionally substituted by one or more substituents selected from fluoro, —O—R and C 1-6 alkyl, wherein the latter alkyl moiety is itself optionally substituted by one or more fluoro atoms);
  • R a , R b and R c independently represent hydrogen or C 1-6 alkyl (optionally substituted by one or more fluoro atoms);
  • X 1 represents —N(R 2 )(R 3 );
  • R 2 and R 3
  • Q 1 , Q 2 , Q 3 , Q 4 and Q 5 each independently represent one or more substituents selected from halo, C 1-6 alkyl, —OC 1-6 alkyl (which latter two alkyl moieties may themselves be optionally substituted by one or more halo, e.g.
  • n1 and n2 independently represent 0 or 1 (hence, the X a -containing ring may be 3-, 4- or 5-membered, or (when m is 2), 6-membered); X a represents —C(R a1 )(R b1 ) m — or —N(R c1 )—; m represents 1 or 2; each R a1 and R b1 independently represents fluoro, hydrogen or C 1-6 alkyl; R c1 represents hydrogen or C 1-6 alkyl; X b represents C(R d ), N, O (in which case L 2 is not present) or C ⁇ O (in which case L 2 is also
  • L 2 may represent hydrogen, halo, —OR f , —C(O)—R g , C 1-6 alkyl (optionally substituted by one or more halo, e.g. fluoro atoms) or an aromatic group (optionally substituted by one or more substituents selected from halo, C 1-6 alkyl (itself optionally substituted by one or more substituents selected from fluoro, —CF 3 and/or —SF 5 ), —OC 1-6 alkyl (itself optionally substituted by one or more fluoro atoms), —O— phenyl (itself optionally substituted by halo, C 1-6 alkyl, C 1-6 fluoroalkyl and/or —OC 1-6 alkyl) or —SF 5 ); R f represents hydrogen, C 1-6 alkyl (optionally substituted by one or more fluoro) or an aromatic group (itself optionally substituted by one or more substituents selected from hal
  • salts include acid addition salts and base addition salts.
  • Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound of formula I with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.
  • the pharmaceutically acceptable acid addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms that the compounds of formula (I) are able to form.
  • These pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid.
  • Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e.
  • butanedioic acid maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
  • prodrug of a relevant compound of the invention includes any compound that, following oral or parenteral administration, is metabolised in vivo to form that compound in an experimentally-detectable amount, and within a predetermined time (e.g. within a dosing interval of between 6 and 24 hours (i.e. once to four times daily)).
  • parenteral administration includes all forms of administration other than oral administration.
  • Prodrugs of compounds of the invention may be prepared by modifying functional groups present on the compound in such a way that the modifications are cleaved, in vivo when such prodrug is administered to a mammalian subject. The modifications typically are achieved by synthesising the parent compound with a prodrug substituent.
  • Prodrugs include compounds of the invention wherein a hydroxyl, amino, sulfhydryl, carboxy or carbonyl group in a compound of the invention is bonded to any group that may be cleaved in vivo to regenerate the free hydroxyl, amino, sulfhydryl, carboxy or carbonyl group, respectively.
  • prodrugs include, but are not limited to, esters and carbamates of hydroxy functional groups, esters groups of carboxyl functional groups, N-acyl derivatives and N-Mannich bases. General information on prodrugs may be found e.g. in Bundegaard, H. “Design of Prodrugs” p. 1-92, Elesevier, New York-Oxford (1985).
  • Compounds of the invention may contain double bonds and may thus exist as E (entussi) and Z (zusammen) geometric isomers about each individual double bond. Positional isomers may also be embraced by the compounds of the invention. All such isomers (e.g. if a compound of the invention incorporates a double bond or a fused ring, the cis- and trans-forms, are embraced) and mixtures thereof are included within the scope of the invention (e.g. single positional isomers and mixtures of positional isomers may be included within the scope of the invention).
  • tautomer or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier.
  • proton tautomers also known as prototropic tautomers
  • Valence tautomers include interconversions by reorganisation of some of the bonding electrons.
  • Compounds of the invention may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism.
  • Diastereoisomers may be separated using conventional techniques, e.g. chromatography or fractional crystallisation. The various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques.
  • the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation or epimerisation (i.e. a ‘chiral pool’ method), by reaction of the appropriate starting material with a ‘chiral auxiliary’ which can subsequently be removed at a suitable stage, by derivatisation (i.e.
  • a resolution for example with a homochiral acid followed by separation of the diastereomeric derivatives by conventional means such as chromatography, or by reaction with an appropriate chiral reagent or chiral catalyst all under conditions known to the skilled person.
  • stereoisomers including but not limited to diastereoisomers, enantiomers and atropisomers
  • mixtures thereof e.g. racemic mixtures
  • stereochemistry of any particular chiral atom is not specified, then all stereoisomers are contemplated and included as the compounds of the invention. Where stereochemistry is specified by a solid wedge or dashed line representing a particular configuration, then that stereoisomer is so specified and defined.
  • the compounds of the present invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.
  • the present invention also embraces isotopically-labeled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (or the most abundant one found in nature). All isotopes of any particular atom or element as specified herein are contemplated within the scope of the compounds of the invention.
  • Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 O, 17 O, 18 O, 32 P, 33 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I.
  • Certain isotopically-labeled compounds of the present invention e.g., those labeled with 3 H and 14 C
  • Tritiated ( 3 H) and carbon-14 ( 14 C) isotopes are useful for their ease of preparation and detectability.
  • isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the Scheme 1 and/or in the Examples herein below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • C 1-q alkyl groups (where q is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of two or three, as appropriate) of carbon atoms, be branched-chain, and/or cyclic (so forming a C 3-q -cycloalkyl group).
  • Such cycloalkyl groups may be monocyclic or bicyclic and may further be bridged. Further, when there is a sufficient number (i.e. a minimum of four) of carbon atoms, such groups may also be part cyclic.
  • Such alkyl groups may also be saturated or, when there is a sufficient number (i.e. a minimum of two) of carbon atoms, be unsaturated (forming, for example, a C 2-q alkenyl or a C 2-q alkynyl group).
  • C 3-q cycloalkyl groups may be monocyclic or bicyclic alkyl groups, which cycloalkyl groups may further be bridged (so forming, for example, fused ring systems such as three fused cycloalkyl groups).
  • Such cycloalkyl groups may be saturated or unsaturated containing one or more double bonds (forming for example a cycloalkenyl group).
  • Substituents may be attached at any point on the cycloalkyl group. Further, where there is a sufficient number (i.e. a minimum of four) such cycloalkyl groups may also be part cyclic.
  • halo when used herein, preferably includes fluoro, chloro, bromo and iodo.
  • Heterocyclic groups when referred to herein may include aromatic or non-aromatic heterocyclic groups, and hence encompass heterocycloalkyl and hetereoaryl.
  • aromatic or non-aromatic 5- or 6-membered rings may be heterocyclic groups (as well as carbocyclic groups) that have 5- or 6-members in the ring.
  • Heterocycloalkyl groups that may be mentioned include non-aromatic monocyclic and bicyclic heterocycloalkyl groups in which at least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom), and in which the total number of atoms in the ring system is between 3 and 20 (e.g. between three and ten, e.g between 3 and 8, such as 5- to 8-). Such heterocycloalkyl groups may also be bridged. Further, such heterocycloalkyl groups may be saturated or unsaturated containing one or more double and/or triple bonds, forming for example a C 2-q heterocycloalkenyl (where q is the upper limit of the range) group.
  • q is the upper limit of the range
  • C 2-q heterocycloalkyl groups that may be mentioned include 7-azabicyclo[2.2.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl, 6-azabicyclo[3.2.1]-octanyl, 8-azabicyclo-[3.2.1]octanyl, aziridinyl, azetidinyl, dihydropyranyl, dihydropyridyl, dihydropyrrolyl (including 2,5-dihydropyrrolyl), dioxolanyl (including 1,3-dioxolanyl), dioxanyl (including 1,3-dioxanyl and 1,4-dioxanyl), dithianyl (including 1,4-dithianyl), dithiolanyl (including 1,3-dithiolanyl), imidazolidinyl, imidazolinyl, morpholinyl, 7-oxabicyclo[2.2.1]heptanyl, 6-oxabicycl
  • heterocycloalkyl groups may, where appropriate, be located on any atom in the ring system including a heteroatom.
  • the point of attachment of heterocycloalkyl groups may be via any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system.
  • Heterocycloalkyl groups may also be in the N- or S-oxidised form. Heterocycloalkyl mentioned herein may be stated to be specifically monocyclic or bicyclic.
  • Aryl groups that may be mentioned include C 6-20 , such as C 6-12 (e.g. C 6-10 ) aryl groups. Such groups may be monocyclic, bicyclic or tricyclic and have between 6 and 12 (e.g. 6 and 10) ring carbon atoms, in which at least one ring is aromatic.
  • C 6-10 aryl groups include phenyl, naphthyl and the like, such as 1,2,3,4-tetrahydronaphthyl.
  • the point of attachment of aryl groups may be via any atom of the ring system. For example, when the aryl group is polycyclic the point of attachment may be via atom including an atom of a non-aromatic ring. However, when aryl groups are polycyclic (e.g. bicyclic or tricyclic), they are preferably linked to the rest of the molecule via an aromatic ring. Most preferred aryl groups that may be mentioned herein are “phenyl”.
  • heteroaryl when used herein refers to an aromatic group containing one or more heteroatom(s) (e.g. one to four heteroatoms) preferably selected from N, O and S.
  • Heteroaryl groups include those which have between 5 and 20 members (e.g. between 5 and 10) and may be monocyclic, bicyclic or tricyclic, provided that at least one of the rings is aromatic (so forming, for example, a mono-, bi-, or tricyclic heteroaromatic group).
  • the heteroaryl group is polycyclic the point of attachment may be via any atom including an atom of a non-aromatic ring.
  • heteroaryl groups are polycyclic (e.g.
  • bicyclic or tricyclic they are preferably linked to the rest of the molecule via an aromatic ring.
  • Heteroaryl groups that may be mentioned include 3,4-dihydro-1H-isoquinolinyl, 1,3-dihydroisoindolyl, 1,3-dihydroisoindolyl (e.g. 3,4-dihydro-1H-isoquinolin-2-yl, 1,3-dihydroisoindol-2-yl, 1,3-dihydroisoindol-2-yl; i.e.
  • heteroaryl groups that are linked via a non-aromatic ring or, preferably, acridinyl, benzimidazolyl, benzodioxanyl, benzodioxepinyl, benzodioxolyl (including 1,3-benzodioxolyl), benzofuranyl, benzofurazanyl, benzothiadiazolyl (including 2,1,3-benzothiadiazolyl), benzothiazolyl, benzoxadiazolyl (including 2,1,3-benzoxadiazolyl), benzoxazinyl (including 3,4-dihydro-2H-1,4-benzoxazinyl), benzoxazolyl, benzomorpholinyl, benzoselenadiazolyl (including 2,1,3-benzoselenadiazolyl), benzothienyl, carbazolyl, chromanyl, cinnolinyl, furanyl, imidazolyl, imidazo[1,
  • heteroaryl groups may, where appropriate, be located on any atom in the ring system including a heteroatom.
  • the point of attachment of heteroaryl groups may be via any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system.
  • Heteroaryl groups may also be in the N- or S-oxidised form.
  • Heteroaryl groups mentioned herein may be stated to be specifically monocyclic or bicyclic. When heteroaryl groups are polycyclic in which there is a non-aromatic ring present, then that non-aromatic ring may be substituted by one or more ⁇ O group.
  • Most preferred heteroaryl groups that may be mentioned herein are 5- or 6-membered aromatic groups containing 1, 2 or 3 heteroatoms (e.g. preferably selected from nitrogen, oxygen and sulfur).
  • the heteroaryl group is monocyclic or bicyclic.
  • the heteroaryl may consist of a five-, six- or seven-membered monocyclic ring (e.g. a monocyclic heteroaryl ring) fused with another five-, six- or seven-membered ring (e.g. a monocyclic aryl or heteroaryl ring).
  • Heteroatoms that may be mentioned include phosphorus, silicon, boron and, preferably, oxygen, nitrogen and sulfur.
  • aromatic groups When “aromatic” groups are referred to herein, they may be aryl or heteroaryl.
  • aromatic linker groups When “aromatic linker groups” are referred to herein, they may be aryl or heteroaryl, as defined herein, any may be monocyclic or polycyclic (e.g. bicyclic) and attached to the remainder of the molecule via any possible atoms of that linker group. However, it may specifically be mentioned that the linker group is a heteroaromatic linker group, in which case such a moiety is aromatic and has to contain at least one heteroatom.
  • a group may be substituted by one or more substituents (e.g. selected from C 1-6 alkyl), then those substituents (e.g. alkyl groups) are independent of one another. That is, such groups may be substituted with the same substituent (e.g. same alkyl substituent) or different (e.g. alkyl) substituents.
  • substituents e.g. selected from C 1-6 alkyl
  • this represents one or more optional substituents on the bicycle to which it is attached, and such optional substituents may be situated on either (or both) rings of such bicycle (i.e. the N-containing 5-membered ring and/or the X a -containing ring).
  • compounds of the invention that are the subject of this invention include those that are stable. That is, compounds of the invention include those that are sufficiently robust to survive isolation from e.g. a reaction mixture to a useful degree of purity.
  • R 2 and R 3 are linked together to form a “fused” bicyclic ring, it is of the following type:
  • n1 and n2 independently represent 1.
  • More preferred compounds of the invention include those in which:
  • R 1 represents hydrogen; R a and R b independently represent hydrogen; L 1 represents —CH 2 —; when X 1 represents a heteroaromatic linker group (where the point of attachment may be via any atom of the ring system), then it in a major aspect of the invention:
  • compounds of the invention comprise:
  • ring A which is an aromatic ring containing at least one to three (e.g. one or two) heteroatoms, preferably contains at least one nitrogen atom;
  • ring B is more preferably also an aromatic ring (e.g. a 5- or especially a 6-membered aromatic ring), preferably containing at least one nitrogen atom.
  • Ring A of the compounds of the invention are represented as follows:
  • Monocyclic heteroaryl groups that may be mentioned include 5- or 6-membered rings containing one to four heteroatoms (preferably selected from nitrogen, oxygen and sulfur). It is preferred that Ring B of the compounds of the invention are represented as follows:
  • “SUB” may be a relevant optional substituent (or more than when relevant substituent, where possible) on a carbon atom or, where possible, on a heteroatom e.g. on a NH, thus replacing the H.
  • Preferred substituents (when present; e.g such optional substituents may be absent or there may be one) on ring B include C 1-3 alkyl (e.g. methyl) or halo (e.g. bromo or, more preferably, chloro).
  • Other preferred substituents on ring B include —OC 1-6 alkyl (e.g. —OC 1-3 alkyl, such as —OCH 3 ).
  • Preferred substituents (when present; e.g such optional substituents may be absent or there may be one) on ring B include C 1-3 alkyl (e.g. methyl) or halo (e.g. bromo or, more preferably, chloro). Preferred substituents (when present; preferably, there may be one or two substituents) on ring A include C 1-3 alkyl (e.g. methyl or ethyl).
  • L 2 represents an aromatic group (e.g. phenyl or pyridyl) and such groups are substituted
  • preferred substituents include halo and especially —OC 1-3 alkyl (e.g. —O-methyl), where the latter is substituted by fluoro, so forming for example a —OCF 3 group.
  • Ring A and Ring B may be represented as follows:
  • Certain compounds of the invention are mentioned (e.g. hereinbefore) for use in the treatment of tuberculosis. Certain of such compounds mentioned herein may also be novel per se. And certain of such compounds mentioned herein may be novel as medicaments/pharmaceuticals (or novel as a component of a pharmaceutical composition/formulation). Hence, in further aspects of the invention, there is provided the following compounds per se or following compounds for use as pharmaceuticals/medicaments (in the latter case such compounds may be components of a pharmaceutical composition/formulation):
  • R 2 and R 3 may represent either (i) or (ii) mentioned herein.
  • R 2 and R 3 may represent either a, b or c as defined in the sub-definitions (e.g. in aspect (I) above).
  • the compounds according to the invention have surprisingly been shown to be suitable for the treatment of a bacterial infection including a mycobacterial infection, particularly those diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis (including the latent and drug resistant form thereof).
  • the present invention thus also relates to compounds of the invention as defined hereinabove, for use as a medicine, in particular for use as a medicine for the treatment of a bacterial infection including a mycobacterial infection.
  • Such compounds of the invention may act by interfering with ATP synthase in M. tuberculosis , with the inhibition of cytochrome bc 1 activity being the primary mode of action.
  • Cytochrome bc 1 is an essential component of the electron transport chain required for ATP synthesis.
  • the present invention also relates to the use of a compound of the invention, as well as any of the pharmaceutical compositions thereof as described hereinafter for the manufacture of a medicament for the treatment of a bacterial infection including a mycobacterial infection.
  • the invention provides a method of treating a patient suffering from, or at risk of, a bacterial infection, including a mycobacterial infection, which comprises administering to the patient a therapeutically effective amount of a compound or pharmaceutical composition according to the invention.
  • the compounds of the present invention also show activity against resistant bacterial strains.
  • the compounds can treat a bacterial infection it is meant that the compounds can treat an infection with one or more bacterial strains.
  • the invention also relates to a composition
  • a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to the invention.
  • the compounds according to the invention may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs.
  • an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirable in unitary dosage form suitable, in particular, for administration orally or by parenteral injection.
  • any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations.
  • the pharmaceutical composition will preferably comprise from 0.05 to 99% by weight, more preferably from 0.1 to 70% by weight, even more preferably from 0.1 to 50% by weight of the active ingredient(s), and, from 1 to 99.95% by weight, more preferably from 30 to 99.9% by weight, even more preferably from 50 to 99.9% by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.
  • the pharmaceutical composition may additionally contain various other ingredients known in the art, for example, a lubricant, stabilising agent, buffering agent, emulsifying agent, viscosity-regulating agent, surfactant, preservative, flavouring or colorant.
  • a lubricant for example, a lubricant, stabilising agent, buffering agent, emulsifying agent, viscosity-regulating agent, surfactant, preservative, flavouring or colorant.
  • Unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.
  • the daily dosage of the compound according to the invention will, of course, vary with the compound employed, the mode of administration, the treatment desired and the mycobacterial disease indicated. However, in general, satisfactory results will be obtained when the compound according to the invention is administered at a daily dosage not exceeding 1 gram, e.g. in the range from 10 to 50 mg/kg body weight.
  • the present compounds may be combined with other antibacterial agents in order to effectively combat bacterial infections.
  • the present invention also relates to a combination of (a) a compound according to the invention, and (b) one or more other antibacterial agents.
  • the present invention also relates to a combination of (a) a compound according to the invention, and (b) one or more other antibacterial agents, for use as a medicine.
  • the present invention also relates to the use of a combination or pharmaceutical composition as defined directly above for the treatment of a bacterial infection.
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of (a) a compound according to the invention, and (b) one or more other antibacterial agents, is also comprised by the present invention.
  • the weight ratio of (a) the compound according to the invention and (b) the other antibacterial agent(s) when given as a combination may be determined by the person skilled in the art. Said ratio and the exact dosage and frequency of administration depends on the particular compound according to the invention and the other antibacterial agent(s) used, the particular condition being treated, the severity of the condition being treated, the age, weight, gender, diet, time of administration and general physical condition of the particular patient, the mode of administration as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. A particular weight ratio for the present compound of the invention and another antibacterial agent may range from 1/10 to 10/1, more in particular from 1/5 to 5/1, even more in particular from 1/3 to 3/1.
  • the compounds according to the invention and the one or more other antibacterial agents may be combined in a single preparation or they may be formulated in separate preparations so that they can be administered simultaneously, separately or sequentially.
  • the present invention also relates to a product containing (a) a compound according to the invention, and (b) one or more other antibacterial agents, as a combined preparation for simultaneous, separate or sequential use in the treatment of a bacterial infection.
  • antibacterial agents which may be combined with the compounds of the invention are for example antibacterial agents known in the art.
  • the compounds of the invention may be combined with antibacterial agents known to interfere with the respiratory chain of Mycobacterium tuberculosis , including for example direct inhibitors of the ATP synthase (e.g. bedaquiline, bedaquiline fumarate or any other compounds that may have be disclosed in the prior art, e.g. compounds disclosed in WO2004/011436), inhibitors of ndh2 (e.g. clofazimine) and inhibitors of cytochrome bd.
  • direct inhibitors of the ATP synthase e.g. bedaquiline, bedaquiline fumarate or any other compounds that may have be disclosed in the prior art, e.g. compounds disclosed in WO2004/011436
  • inhibitors of ndh2 e.g. clofazimine
  • inhibitors of cytochrome bd e.g. cytochrome bd.
  • the compounds according to the invention can generally be prepared by a succession of steps, each of which may be known to the skilled person or described herein.
  • amide coupling reaction conditions for example in the presence of a suitable coupling reagent (e.g. 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (or hydrochloride thereof) or N,N′-disuccinimidyl carbonate), optionally in the presence of a suitable base (e.g.
  • a suitable coupling reagent e.g. 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (or hydrochloride thereof) or N,N′-disuccinimidyl carbonate
  • a suitable base e.g.
  • the carboxylic acid group of the compound of formula (IV) may first be converted under standard conditions to the corresponding acyl chloride (e.g.
  • LG 2 represents a suitable leaving group, such as iodo, bromo, chloro or a sulfonate group (for example a type of group that may be deployed for a coupling), with a compound of formula (V),
  • integers are as hereinbefore defined, under standard conditions, for example optionally in the presence of an appropriate metal catalyst (or a salt or complex thereof) such as Pd(dba) 2 , Pd(OAc) 2 , Cu, Cu(OAc) 2 , CuI, NiCl 2 or the like, with an optional additive such as Ph 3 P, X-phos or the like, in the presence of an appropriate base (e.g. t-BuONa, or the like) in a suitable solvent (e.g. dioxane or the like) under reaction conditions known to those skilled in the art.
  • an appropriate metal catalyst or a salt or complex thereof
  • Ph 3 P, X-phos or the like e.g. t-BuONa, or the like
  • a suitable solvent e.g. dioxane or the like
  • reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art, such as extraction, crystallization and chromatography. It is further evident that reaction products that exist in more than one enantiomeric form, may be isolated from their mixture by known techniques, in particular preparative chromatography, such as preparative HPLC, chiral chromatography. Individual diastereoisomers or individual enantiomers can also be obtained by Supercritical Fluid Chromatography (SCF).
  • SCF Supercritical Fluid Chromatography
  • the starting materials and the intermediates are compounds that are either commercially available or may be prepared according to conventional reaction procedures generally known in the art.
  • Triphenylphosphine (1.89 g, 7.20 mmol), imidazole (735 mg, 10.8 mmol) and iodine (1.37 g, 5.40 mmol) were added to a solution of tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate (CAS [1147557-97-8], 768 mg, 3.60 mmol) in toluene (50 mL). The resulting mixture was refluxed for 1 hour. The mixture was cooled to 25° C., washed with water (100 mL) and brine (50 mL). The separated organic layer was dried, filtered and the filtrate was concentrated under vacuum. The residue was purified by flash column chromatography over silica gel (eluent: petroleum ether/ethyl acetate 1/0 to 1/1) to give intermediate R (1.20 g, yield: 93%).
  • Compound 1 was prepared in the same way as Compound 2 starting from intermediate L and intermediate AZ, yielding 0.037 g, 25%.
  • intermediate A′′ (0.13 g, 0.327 mmol) in MeOH (20 mL) was added Raney Nickel (65 mg) and ammonia 4M in MeOH (1 mL) under N 2 .
  • the suspension was degassed under vacuum and purged with H2 several times.
  • the mixture was stirred under H2 (50 psi) at 25° C. for 10 hours.
  • the suspension was filtered through a pad of Celite® was washed with MeOH (20 mL). The combined filtrates were concentrated to dryness to give intermediate B′′, 0.12 g, 92%.
  • intermediate C′′ was prepared in the same way as intermediate A′′ starting from 2-chloroquinoline-6-carbonitrile CAS [78060-54-5] and 5-fluorooctahydro-cyclopenta[c]pyrrole CAS [1554431-13-8] to give 0.15 g, 91%.
  • intermediate D′′ was prepared in the same way as intermediate B′′ starting from intermediate C′′ to give 0.15 g, 99%.
  • intermediate F′′ was prepared in the same way as intermediate B′′ starting from intermediate E′′ to give 0.02 g, 92%.
  • the residue was purified by high performance liquid chromatography (Phenomenex Gemini 150 ⁇ 25 mm ⁇ 10 um, 25 ml/min, mobile phase water (containing 0.1% NH 3 .H 2 O)/Acetonitrile, gradient from 45/55 to 25/85). The desired fraction was collected and evaporated to remove off CH 3 CN in vacuum. The residue was lyophilized to give Compound 7, 0.052 g, 37%.
  • intermediate BM 5 g, 24.36 mmol
  • MeOH MeOH
  • intermediate BN (0.55 g, 2.46 mmol) in MeOH (25 mL) and water (5 mL) was added lithium hydroxide monohydrate (0.52 g, 12.32 mmol). The mixture was stirred at room temperature for 10 h. The solvent was removed in vacuum to dryness. The residue was purified by high performance liquid chromatography (DuraShell 150 ⁇ 25 mm ⁇ 5 ⁇ m, 25 ml/min, water (containing 0.05% HCl)/Acetonitrile from 100/0 to 70/30). The desired fraction was collected and evaporated to remove off acetonitrile in vacuum. The residue was lyophilized to give intermediate BO, 0.4 g, 78%.
  • intermediate G′′ was prepared in the same way as intermediate A′′ starting from 2-chloroquinoline-6-carbonitrile (CAS [78060-54-5] and 1-(4-Trifluoromethoxy-phenyl)-piperazine CAS [187669-62-1] affording 0.15 g, 84%.
  • intermediate H′′ was prepared in the same way as intermediate B′′ starting from intermediate G′′ affording 0.15 g, 96%.
  • intermediate J′′ (0.18 g, 0.485 mmol) in ammonia 4M in methanol (10 mL) was added Raney Nickel (50 mg) under N 2 .
  • the suspension was degassed under vacuum and purged with H2 several times.
  • the mixture was stirred under H2 (15 psi) at 25° C. for 10 hours.
  • the suspension was filtered through a pad of Celite® and the pad was washed with methanol (10 mL). The combined filtrates were concentrated in vacuum to give intermediate K′′, 0.18 g, 99%.
  • the residue was purified by high performance liquid chromatography (Waters Xbridge Prep OBD C18 150 ⁇ 30 ⁇ 5 ⁇ , 25 ml/min, mobile phase: water (containing 0.05% NH 3 .H 2 O)/acetonitrile, gradient from 52/58 to 22/78). The desired fraction was collected and evaporated to remove off acetonitrile in vacuum. The residue was lyophilized to give Compound 11, 0.091 g, 34%.
  • Intermediate AV was prepared in the same way as intermediate S, starting from intermediate R and Phenylboronic acid CAS [98-80-6], yielding 0.3 g, 62%.
  • intermediate AW was prepared in the same way as intermediate T, starting from intermediate AV, yielding 0.27 g, 99%.
  • the crude product was purified by preparative LC (irregular silica 15-40 m, 24 g GraceResolv, dry loading (silica), mobile phase: heptane/EtOAc 90/10 to 50/50) to obtain 0.143 g of intermediate O′′ as yellow solid (67%).
  • the residue was purified by high performance liquid chromatography (Waters Xbridge Prep OBD C18 150 ⁇ 30 ⁇ 5 ⁇ , 20 ml/min, water (containing 0.05% NH 3 .H 2 O)/Methanol gradient from 25/75 to 0/100). The desired fraction was collected and evaporated to remove off methanol in vacuum. The residue was lyophilized affording Compound 15, 0.054 g, 38%.
  • Intermediate V′′ was prepared in accordance with the following procedure: aqueous sodium hydroxide 8M (e.g. about 164 mmol) is added to a solution of intermediate U′′ (e.g. about 32.1 mmol) in THF (e.g. about 39 mL) and methanol (e.g. about 39 mL). The resulting mixture may be stirred at e.g. 70° C. overnight. HCl (1M) may be added to the mixture until pH-7-8. The resulting precipitate may be filtered and dried under high vacuum to give intermediate V′′ as an off-white solid.
  • aqueous sodium hydroxide 8M e.g. about 164 mmol
  • THF e.g. about 39 mL
  • methanol e.g. about 39 mL
  • the crude product was purified by preparative LC (Regular SiOH 30 ⁇ m, 25 g Interchim, dry loading (Celite®), mobile phase gradient DCM/MeOH from 100/0 to 95/5) to give 0.152 g of Compound 27 as a white solid (38%).
  • the crude product was purified by preparative LC (irregular SiOH, 15-40 ⁇ m, 80 g, Grace, dry loading (silica), mobile phase gradient Heptane/EtOAc from 90/10 to 70/30) to give 0.3 g of intermediate W′′ as a white solid (40%).
  • intermediate X′′ was prepared in the same way as intermediate B′′, starting from intermediate W′′, and yielding 0.291 g, as a white powder, 97%.
  • HPLC High Performance Liquid Chromatography
  • MS Mass Spectrometer
  • MSD Mass Selective Detector
  • DAD Diode Array Detector
  • HPLC High Performance Liquid Chromatography
  • MS Mass Spectrometer
  • SQL Single Quadrupole Detector
  • RT room temperature
  • BEH bridged ethylsiloxane/silica hybrid
  • HSS High Strength Silica
  • DAD Diode Array Detector
  • MSD Mass Selective Detector
  • DAD Diode Array Detector
  • Method D Agilent: Agilent: TC- A: CF 3 COOH 90% A for 0.8 10.5 1100/1200- C18 (5 ⁇ m, 0.1% in water, 0.8 min, to 20% A 50 DAD and 2.1 ⁇ 50 mm) B: CF 3 COOH in 3.7 min, held MSD 0.05% in for 3 min, back to CH 3 CN 90% A in 2 min.
  • Method E Agilent: Waters: A: NH 4 OH 100% A for 1 min, 0.8 10.5 1100/1200- XBridge TM 0.05% in water, to 40% A in 40 DAD and Shield RP18 B: CH 3 CN 4 min, held for 50 MSD (5 ⁇ m, 2.5 min, back to 2.1 ⁇ 50 mm) 100% A in 2 min.
  • fluorescence was measured on a Gemini EM Microplate Reader with 543 excitation and 590 nm emission wavelengths and MIC 50 and/or pIC 50 values (or the like, e.g. IC 50 , IC 90 , pIC 90 , etc) were (or may be) calculated.
  • the 90% minimal inhibitory concentration (MIC 90 ) is determined as the concentration with no visual bacterial growth.
  • Bactericidal or bacteriostatic activity of the compounds can be determined in a time kill assay using the broth dilution method.
  • a time kill assay on Mycobacterium tuberculosis strain H37RV
  • the starting inoculum of M. tuberculosis is 10 6 CFU/ml in Middlebrook (1 ⁇ ) 7H9 broth.
  • the antibacterial compounds are used at the concentration of 0.1 to 10 times the MIC 90 .
  • Tubes receiving no antibacterial agent constitute the culture growth control. The tubes containing the microorganism and the test compounds are incubated at 37° C.
  • Test 4 See Also Test 1 Above; in this Test a Different Strain of Mycobacterium tuberculosis Strain is Employed
  • pIC 50 values may be recorded below in ⁇ g/mL.
  • Compounds of the invention/examples may typically have an IC 90 value from 0.01 to 10 ⁇ g/ml.
  • Compounds of the invention/examples, for example when tested in Test 1 or Test 2 described above may typically have a pIC 50 from 3 to 10 (e.g. from 4.0 to 9.0, such as from 5.0 to 8.0)
  • Compounds of the examples were tested in Test 1 described above (in section “Pharmacological Examples”) and the following results were obtained:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
US15/736,524 2015-07-02 2016-07-01 Antibacterial Compounds Abandoned US20180155341A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15174936.3 2015-07-02
EP15174936 2015-07-02
EP16174713 2016-06-16
EP16174718.3 2016-06-16
EP16174718 2016-06-16
EP16174713.4 2016-06-16
PCT/EP2016/065503 WO2017001661A1 (fr) 2015-07-02 2016-07-01 Composés antibactériens

Publications (1)

Publication Number Publication Date
US20180155341A1 true US20180155341A1 (en) 2018-06-07

Family

ID=56289523

Family Applications (6)

Application Number Title Priority Date Filing Date
US15/736,524 Abandoned US20180155341A1 (en) 2015-07-02 2016-07-01 Antibacterial Compounds
US15/736,375 Active US10364232B2 (en) 2015-07-02 2016-07-01 Antibacterial compounds
US16/460,334 Abandoned US20190330189A1 (en) 2015-07-02 2019-07-02 Antibacterial compounds
US16/848,337 Active US11180472B2 (en) 2015-07-02 2020-04-14 Antibacterial compounds
US17/477,970 Active 2036-10-06 US11866419B2 (en) 2015-07-02 2021-09-17 Antibacterial compounds
US18/523,171 Pending US20240132470A1 (en) 2015-07-02 2023-11-29 Antibacterial Compounds

Family Applications After (5)

Application Number Title Priority Date Filing Date
US15/736,375 Active US10364232B2 (en) 2015-07-02 2016-07-01 Antibacterial compounds
US16/460,334 Abandoned US20190330189A1 (en) 2015-07-02 2019-07-02 Antibacterial compounds
US16/848,337 Active US11180472B2 (en) 2015-07-02 2020-04-14 Antibacterial compounds
US17/477,970 Active 2036-10-06 US11866419B2 (en) 2015-07-02 2021-09-17 Antibacterial compounds
US18/523,171 Pending US20240132470A1 (en) 2015-07-02 2023-11-29 Antibacterial Compounds

Country Status (27)

Country Link
US (6) US20180155341A1 (fr)
EP (3) EP4074378A1 (fr)
JP (2) JP2018519302A (fr)
KR (2) KR20180022826A (fr)
CN (3) CN108235704B (fr)
AU (3) AU2016287477B2 (fr)
BR (1) BR112017028318B1 (fr)
CA (2) CA2986326A1 (fr)
CL (1) CL2017003404A1 (fr)
CO (1) CO2017013408A2 (fr)
DK (1) DK3316969T3 (fr)
EA (2) EA201890201A1 (fr)
ES (1) ES2914681T3 (fr)
HK (2) HK1249468A1 (fr)
HR (1) HRP20220339T1 (fr)
IL (2) IL256379A (fr)
LT (1) LT3316969T (fr)
MA (1) MA42293A (fr)
MD (1) MD3316969T2 (fr)
MX (2) MX2017016789A (fr)
PE (1) PE20180520A1 (fr)
PH (2) PH12017502298B1 (fr)
PL (1) PL3316969T3 (fr)
RS (1) RS63201B1 (fr)
SI (1) SI3316969T1 (fr)
UA (1) UA125171C2 (fr)
WO (2) WO2017001661A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243224A1 (fr) * 2019-05-28 2020-12-03 Shionogi & Co., Ltd. Médicament destiné au traitement d'une infection mycobactérienne caractérisé par la combinaison d'un inhibiteur bc1 avec de la clarithromycine ou de l'azithromycine et de la clofazimine
US11820767B2 (en) 2015-09-17 2023-11-21 University Of Notre Dame Du Lac Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3868752A1 (fr) 2014-08-28 2021-08-25 Asceneuron SA Inhibiteurs de la glycosidase
EP4074378A1 (fr) 2015-07-02 2022-10-19 Janssen Sciences Ireland Unlimited Company Composés antibactériens
ES2930749T3 (es) 2015-07-02 2022-12-21 Hoffmann La Roche Lactamas bicíclicas como inhibidores de la proteína de interacción con el receptor 1 (RIP1) cinasa para tratar, por ejemplo, enfermedades inflamatorias
MA43677A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
EP3419972B1 (fr) 2016-02-25 2023-07-26 Asceneuron SA Inhibiteurs de glycosidases
CN109071526B (zh) 2016-02-25 2023-02-28 阿森纽荣股份公司 哌嗪衍生物的酸加成盐
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
SI3429591T1 (sl) 2016-03-16 2023-07-31 Kura Oncology, Inc. Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe
CN109476657A (zh) 2016-06-16 2019-03-15 爱尔兰詹森科学公司 作为抗细菌剂的杂环化合物
CN109843886B (zh) 2016-10-17 2022-04-19 豪夫迈·罗氏有限公司 二环吡啶酮内酰胺及其使用方法
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
US20200048267A1 (en) * 2017-02-06 2020-02-13 Janssen Pharmaceutica Nv Oga inhibitor compounds
BR112019017901A2 (pt) 2017-03-01 2020-05-12 Janssen Sciences Ireland Unlimited Company Terapia de combinação
EP3672959A1 (fr) 2017-08-24 2020-07-01 Asceneuron SA Inhibiteurs linéaires de la glycosidase
WO2019060365A1 (fr) * 2017-09-20 2019-03-28 Kura Oncology, Inc. Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
JP2020537667A (ja) 2017-10-17 2020-12-24 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
EP3732163A4 (fr) 2017-12-20 2021-07-14 Vanderbilt University Antagonistes du récepteur muscarinique de l'acétylcholine m4
RU2680972C1 (ru) * 2018-02-13 2019-03-01 Федеральное государственное бюджетное научное учреждение "Центральный научно-исследовательский институт туберкулеза" Способ определения длительности химиотерапии туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью МБТ у детей и подростков
US20210009583A1 (en) * 2018-03-12 2021-01-14 University Of Notre Dame Du Lac Deuterated imidazopyridines
CN112074519A (zh) 2018-04-20 2020-12-11 豪夫迈·罗氏有限公司 作为rip1激酶抑制剂用于治疗e.g.肠易激综合征（ibs）的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
WO2020039028A1 (fr) 2018-08-22 2020-02-27 Asceneuron S. A. Inhibiteurs de tétrahydro-benzoazépine glycosidase
WO2020039027A1 (fr) 2018-08-22 2020-02-27 Asceneuron S. A. Inhibiteurs de pyrrolidine glycosidase
CN109503631A (zh) * 2018-12-29 2019-03-22 中国医学科学院医药生物技术研究所 含有二氮杂螺环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法和应用
KR102076958B1 (ko) 2019-06-24 2020-02-13 엘티소재주식회사 헤테로고리 화합물 및 이를 이용한 유기 발광 소자
TW202124379A (zh) 2019-09-10 2021-07-01 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的５，６－雜芳族化合物
WO2021048342A1 (fr) 2019-09-13 2021-03-18 Janssen Sciences Ireland Unlimited Company Composés antibactériens
MX2022003816A (es) 2019-09-30 2022-05-06 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
BR112022005068A2 (pt) 2019-09-30 2022-09-06 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos de 4-quinolinona
EP4081304B1 (fr) 2019-12-27 2024-03-06 Tecnimede, Sociedade Técnico-Medicinal, SA Quinolines antibactériennes
CA3211532A1 (fr) 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Composes antibacteriens
BR112023018655A2 (pt) 2021-03-17 2023-12-12 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
BR112023018654A2 (pt) 2021-03-17 2023-10-03 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
WO2022214520A1 (fr) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Composés antibactériens
WO2022214519A1 (fr) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Composés antibactériens
WO2023275744A1 (fr) 2021-06-29 2023-01-05 TECNIMEDE - Sociedade Técnico-medicinal, SA Composés hétérocycliques pour le traitement de la tuberculose
AU2022377203A1 (en) 2021-10-28 2024-06-13 Janssen Sciences Ireland Unlimited Company Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
TW202413353A (zh) * 2022-06-15 2024-04-01 美商Ｃ４醫藥公司 用於標靶降解smarca2之化合物
WO2024089170A1 (fr) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Composés antibactériens

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015167A2 (fr) * 2012-07-18 2014-01-23 University Of Notre Dame Du Lac Composés anti-infectieux 5,5-hétéroaromatiques
WO2015014993A2 (fr) * 2013-08-02 2015-02-05 Institut Pasteur Korea Composés anti-infectieux
US20180186768A1 (en) * 2015-07-02 2018-07-05 Janssen Sciences Ireland Uc Antibacterial Compounds

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952324A (en) 1994-11-15 1999-09-14 Pharmacia & Upjohn Company Bicyclic oxazine and thiazine oxazolidinone antibacterials
DK0828741T3 (da) 1995-05-11 2001-11-26 Upjohn Co Spirocykliske og bicykliske diazinyl- og carbazinyloxazolidinoner
PT2301544E (pt) 2002-07-25 2012-12-10 Janssen Pharmaceutica Nv Novos inibidores de micobactérias
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
MA27360A1 (fr) 2004-11-23 2005-06-01 Brahim Bennani Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux
JP2010513495A (ja) 2006-12-20 2010-04-30 シェーリング コーポレイション 新規なｊｎｋ阻害剤
TW200901969A (en) * 2007-06-06 2009-01-16 Smithkline Beecham Corp Chemical compounds
TWI498115B (zh) 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
AU2009228293B2 (en) 2008-03-26 2012-11-08 Tennor Therapeutics (Suzhou) Limited Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones
EP2385371B1 (fr) 2008-09-22 2014-10-22 Oregon Health and Science University Méthodes permettant de détecter une infection par le bacille de Koch
WO2010078408A1 (fr) 2008-12-30 2010-07-08 Biogen Idec Ma Inc. Composés hétéroaryles utiles en tant qu'inhibiteurs de kinase raf
CN110483499A (zh) 2009-11-05 2019-11-22 圣母大学 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法
SG10201502109VA (en) 2010-03-18 2015-05-28 Pasteur Institut Korea Anti-infective compounds
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
EP2751103A1 (fr) 2011-09-01 2014-07-09 Irm Llc Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
PT2751104T (pt) 2011-09-01 2019-12-16 Novartis Ag Compostos e composições como inibidores de c-kit quinase
CN104520290B (zh) * 2012-03-02 2020-10-09 基因科技股份有限公司 酰氨基螺环酰胺和磺酰胺衍生物
KR101918469B1 (ko) 2012-06-04 2018-11-15 한국화학연구원 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
KR101650716B1 (ko) 2012-11-22 2016-08-24 한국화학연구원 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물
KR101564425B1 (ko) 2013-11-26 2015-10-30 한국화학연구원 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물
CN105524058B (zh) 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
WO2016073524A1 (fr) 2014-11-03 2016-05-12 The Regents Of The University Of California Multithérapies médicamenteuses pour le traitement de la tuberculose
CN109476657A (zh) 2016-06-16 2019-03-15 爱尔兰詹森科学公司 作为抗细菌剂的杂环化合物
AU2017286370B2 (en) 2016-06-16 2021-09-09 Janssen Sciences Ireland Uc Heterocyclic compounds as antibacte rials
BR112019017901A2 (pt) 2017-03-01 2020-05-12 Janssen Sciences Ireland Unlimited Company Terapia de combinação

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015167A2 (fr) * 2012-07-18 2014-01-23 University Of Notre Dame Du Lac Composés anti-infectieux 5,5-hétéroaromatiques
WO2015014993A2 (fr) * 2013-08-02 2015-02-05 Institut Pasteur Korea Composés anti-infectieux
US20180186768A1 (en) * 2015-07-02 2018-07-05 Janssen Sciences Ireland Uc Antibacterial Compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11820767B2 (en) 2015-09-17 2023-11-21 University Of Notre Dame Du Lac Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
WO2020243224A1 (fr) * 2019-05-28 2020-12-03 Shionogi & Co., Ltd. Médicament destiné au traitement d'une infection mycobactérienne caractérisé par la combinaison d'un inhibiteur bc1 avec de la clarithromycine ou de l'azithromycine et de la clofazimine

Also Published As

Publication number Publication date
AU2016287478A1 (en) 2017-11-30
PH12017502298A1 (en) 2018-06-11
SI3316969T1 (sl) 2022-05-31
IL256391A (en) 2018-02-28
WO2017001661A1 (fr) 2017-01-05
US11866419B2 (en) 2024-01-09
BR112017028318B1 (pt) 2024-02-20
US20230014173A1 (en) 2023-01-19
PH12017502297A1 (en) 2018-06-25
LT3316969T (lt) 2022-03-25
PL3316969T3 (pl) 2022-06-20
UA125171C2 (uk) 2022-01-26
US20200239434A1 (en) 2020-07-30
HK1254677A1 (zh) 2019-07-26
IL256391B (en) 2021-03-25
HRP20220339T1 (hr) 2022-05-13
US11180472B2 (en) 2021-11-23
CA2986326A1 (fr) 2017-01-05
CL2017003404A1 (es) 2018-05-11
PH12017502298B1 (en) 2018-06-11
AU2016287477B2 (en) 2021-10-21
PE20180520A1 (es) 2018-03-14
EP4074378A1 (fr) 2022-10-19
MA42293A (fr) 2018-05-09
JP7099824B2 (ja) 2022-07-12
JP2022043078A (ja) 2022-03-15
US20180186768A1 (en) 2018-07-05
CN113980015A (zh) 2022-01-28
KR20180022826A (ko) 2018-03-06
EP3316969B1 (fr) 2022-03-02
AU2022200385B2 (en) 2024-06-13
EA201890201A1 (ru) 2018-06-29
AU2022200385A1 (en) 2022-02-17
IL256379A (en) 2018-02-28
RS63201B1 (sr) 2022-06-30
CN108235704B (zh) 2021-10-26
JP2018519302A (ja) 2018-07-19
BR112017028318A2 (pt) 2018-09-04
US20240132470A1 (en) 2024-04-25
KR20180022833A (ko) 2018-03-06
US10364232B2 (en) 2019-07-30
ES2914681T3 (es) 2022-06-15
AU2016287478B2 (en) 2021-10-21
MD3316969T2 (ro) 2022-07-31
CN108235704A (zh) 2018-06-29
MX2017016788A (es) 2018-07-06
HK1249468A1 (zh) 2018-11-02
AU2016287477A1 (en) 2017-11-30
US20190330189A1 (en) 2019-10-31
EP3316969A1 (fr) 2018-05-09
JP2018524339A (ja) 2018-08-30
EP3316968A1 (fr) 2018-05-09
WO2017001660A1 (fr) 2017-01-05
EA201890204A1 (ru) 2018-06-29
CN107708809A (zh) 2018-02-16
CA2986331A1 (fr) 2017-01-05
MX2017016789A (es) 2018-06-11
CO2017013408A2 (es) 2018-05-31
DK3316969T3 (da) 2022-05-02

Similar Documents

Publication Publication Date Title
US11866419B2 (en) Antibacterial compounds
US11179396B2 (en) Heterocyclic compounds as antibacterials
AU2017286370B2 (en) Heterocyclic compounds as antibacte rials
US20220088012A1 (en) Combination therapy
US20220340564A1 (en) Antibacterial compounds
US20240199651A1 (en) Antibacterial compounds
US20240182495A1 (en) Antibacterial compounds
OA19129A (en) Heterocyclic compounds as antibacterials.
OA19079A (en) Antibacterial compounds.
OA19126A (en) Heterocyclic compounds as antibacterials
OA18504A (en) Antibacterial compounds.

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: JANSSEN-CILAG, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GUILLEMONT, JEROME EMILE GEORGES;MOTTE, MAGALI MADELEINE SIMONE;REEL/FRAME:054322/0055

Effective date: 20161010

Owner name: JANSSEN PHARMACEUTICA NV, BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RABOISSON, PIERRE JEAN-MARIE BERNARD;TAHRI, ABDELLAH;SIGNING DATES FROM 20160923 TO 20161121;REEL/FRAME:054322/0162

Owner name: JANSSEN SCIENCES IRELAND UC, IRELAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JANSSEN-CILAG;REEL/FRAME:054322/0274

Effective date: 20160616

Owner name: JANSSEN SCIENCES IRELAND UC, IRELAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JANSSEN PHARMACEUTICA NV;REEL/FRAME:054322/0483

Effective date: 20160616

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE